clinical trial · NCT06211764
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
Janssen Research & Development, LLC·phase3·active not recruiting·n = 272
Non-Muscle Invasive Bladder NeoplasmsTAR-200Mitomycin CGemcitabine
brief summary
The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of Bacillus Calmette-Guérin (BCG) therapy and who refused or are unfit for Radical Cystectomy (RC), receiving TAR-200 versus investigator's choice of single agent intravesical chemotherapy.
started
Apr 9, 2024
primary completion
Nov 27, 2030
completion
Apr 14, 2031
last updated
Sep 25, 2026
official title
17000139BLC3004: 17000139BLC3004 [SunRISe-5] Ph III HR NMIBC BCG Exp/UR Pap (N=250)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol